Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (24)	1/17/1999 2:11:00 PM
From: yosi s	Respond to of 423

Thanks Jeffery for your response. "The purpose of this thread is to isolate those stocks which are out of favior and significantly undervalued ( on a relative basis ) based on future expectations. If you have reason to believe this is true about PARS please continue to give us updates on your pick." In responds to that. Pharmos is indeed, undervalue. They Have Alrex and Lotemax now marketed by BOL for eye inflamation and post eye surgery. The US market is over 200 million for both, BOL, should be getting upward of 7% of this market now, and by year end 10% or more. Either way some revenues are coming in. In the next 3-6 months A partner should be signed in for phase 3 and the study should strat soon thereafter. Pharmos should get upfront money, and the cost of phase 3 will be carried by a partner. They will plan to enroll 700 to 1000 patients in a multicentered trial in US and Europe. They got very good press in the Neurosurgical community when they released their phase 2 study.